Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

GKOS – Glaukos Corporation

Float Short %

3.68

Margin Of Safety %

Put/Call OI Ratio

0.35

EPS Next Q Diff

-0.02

EPS Last/This Y

1.94

EPS This/Next Y

0.49

Price

126.08

Target Price

131.79

Analyst Recom

1.38

Performance Q

65.92

Relative Volume

1.37

Beta

0.7

Ticker: GKOS




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-26GKOS116.220.383.672029
2025-12-29GKOS115.570.390.372037
2025-12-30GKOS114.180.390.262060
2025-12-31GKOS112.980.390.362069
2026-01-02GKOS110.720.390.902077
2026-01-05GKOS112.510.400.362094
2026-01-06GKOS112.280.400.212110
2026-01-07GKOS113.80.400.202115
2026-01-08GKOS114.290.400.222121
2026-01-09GKOS112.940.400.172148
2026-01-12GKOS110.980.390.602170
2026-01-13GKOS110.290.400.832188
2026-01-14GKOS104.430.401.202190
2026-01-15GKOS114.440.410.132326
2026-01-16GKOS120.250.380.222482
2026-01-20GKOS123.450.380.111281
2026-01-21GKOS124.240.340.431404
2026-01-22GKOS125.680.354.081408
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-26GKOS116.2347.678.0-0.83
2025-12-29GKOS115.4447.678.0-0.83
2025-12-30GKOS114.1347.678.0-0.83
2025-12-31GKOS112.9047.678.0-0.83
2026-01-02GKOS110.8047.678.0-0.83
2026-01-05GKOS112.5247.677.9-0.83
2026-01-06GKOS112.2847.678.0-0.83
2026-01-07GKOS113.7547.677.9-0.83
2026-01-08GKOS114.2447.678.0-0.83
2026-01-09GKOS112.9847.678.0-0.83
2026-01-12GKOS110.9547.678.0-0.83
2026-01-13GKOS110.2447.578.0-0.83
2026-01-14GKOS104.3247.578.2-0.83
2026-01-15GKOS114.5446.677.6-0.83
2026-01-16GKOS120.2446.677.8-0.83
2026-01-20GKOS123.5446.277.9-0.83
2026-01-21GKOS124.3046.277.9-0.83
2026-01-22GKOS126.0846.277.9-0.83
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-26GKOS-1.23-7.253.72
2025-12-29GKOS-1.23-7.253.72
2025-12-30GKOS-1.23-7.253.72
2025-12-31GKOS-1.23-7.253.72
2026-01-02GKOS-1.23-7.253.72
2026-01-05GKOS-1.23-7.253.72
2026-01-06GKOS-1.23-7.253.72
2026-01-07GKOS-1.23-7.253.72
2026-01-08GKOS-1.23-7.253.72
2026-01-09GKOS-1.23-7.253.72
2026-01-12GKOS-1.22-7.253.72
2026-01-13GKOS-1.23-7.253.68
2026-01-14GKOS-1.23-7.253.68
2026-01-15GKOS-1.23-7.253.68
2026-01-16GKOS-1.23-7.253.68
2026-01-20GKOS-1.23-7.483.68
2026-01-21GKOS-11.12-7.483.68
2026-01-22GKOS-11.12-7.483.68
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

-0.21

Avg. EPS Est. Next Quarter

-0.18

Insider Transactions

-11.12

Institutional Transactions

-7.48

Beta

0.7

Average Sales Estimate Current Quarter

129

Average Sales Estimate Next Quarter

132

Fair Value

Quality Score

49

Growth Score

50

Sentiment Score

91

Actual DrawDown %

23

Max Drawdown 5-Year %

-64.3

Target Price

131.79

P/E

Forward P/E

PEG

P/S

15.39

P/B

9.39

P/Free Cash Flow

EPS

-1.55

Average EPS Est. Cur. Y​

-0.83

EPS Next Y. (Est.)

-0.34

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-18.65

Relative Volume

1.37

Return on Equity vs Sector %

-38.6

Return on Equity vs Industry %

-29.1

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

77.9
Glaukos Corporation
Sector: Healthcare
Industry: Medical Devices
Employees: 995
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
stock quote shares GKOS – Glaukos Corporation Stock Price stock today
news today GKOS – Glaukos Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch GKOS – Glaukos Corporation yahoo finance google finance
stock history GKOS – Glaukos Corporation invest stock market
stock prices GKOS premarket after hours
ticker GKOS fair value insiders trading